# A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

> **NCT02920424** · PHASE1 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** JNJ-56022473
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02920424
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06-30
- **Primary completion:** 2019-02-01
- **Final completion:** 2019-09-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The decision is based on a change in the benefit risk assessment of this drug for the lupus population targeted in this study.
- **Last updated:** 2017-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02920424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02920424, "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02920424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*